Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Laura Vanagas, Victoria Jeffers, Silvina S Bogado, Maria C Dalmasso, William J Sullivan$suffix/text()$suffix/text() & Sergio O Angel. (2012) Toxoplasma histone acetylation remodelers as novel drug targets. Expert Review of Anti-infective Therapy 10:10, pages 1189-1201.
Read now
Read now
Sutapa Mukherjee, Ruma Sarkar, Jaydip Biswas & Madhumita Roy. (2012) Curcumin Inhibits Histone Deacetylase Leading to Cell Cycle Arrest and Apoptosis via Upregulation of p21 in Breast Cancer Cell Lines. International Journal of Green Nanotechnology 4:2, pages 183-197.
Read now
Read now
Rodney F Minchin & Shu Yang. (2010) Endosomal disruptors in non-viral gene delivery. Expert Opinion on Drug Delivery 7:3, pages 331-339.
Read now
Read now
Steve Price & Hazel J Dyke. (2007) Histone deacetylase inhibitors. Expert Opinion on Therapeutic Patents 17:7, pages 745-765.
Read now
Read now
P. Workman. (2004) Drug Discovery Strategies: Technologies to Accelerate Translation from Target to Drug. Journal of Chemotherapy 16:sup4, pages 13-15.
Read now
Read now
Articles from other publishers (64)
Joanna Szczepanek & Andrzej Tretyn. (2023) MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications. Biomolecules 13:11, pages 1590.
Crossref
Crossref
Ying Li, Lei Ding, Shuang Ren, Wen Zhang & Guo-Wu Rao. (2023) Protein Lysine Methyltransferases Inhibitors. Current Medicinal Chemistry 30:27, pages 3060-3089.
Crossref
Crossref
Muhammad Nabeel Asim, Muhammad Ali Ibrahim, Muhammad Imran Malik, Imran Razzak, Andreas Dengel & Sheraz Ahmed. (2022) Histone-Net: a multi-paradigm computational framework for histone occupancy and modification prediction. Complex & Intelligent Systems 9:1, pages 399-419.
Crossref
Crossref
Claudia Pellerito, Sonia Emanuele, Michela Giuliano & Tiziana Fiore. (2022) Organotin(IV) complexes with epigenetic modulator ligands: New promising candidates in cancer therapy. Inorganica Chimica Acta 536, pages 120901.
Crossref
Crossref
Deniz Mortazavi, Behnoush Sohrabi, Meysam Mosallaei, Ziba Nariman-Saleh-Fam, Milad Bastami, Yaser Mansoori, Abdolreza Daraei, Sepideh Zununi Vahed, Shadan Navid, Zahra Saadatian, Tannaz Jamialahmadi, Yong Teng & Amirhossein Sahebkar. (2022) Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer. Journal of Oncology 2022, pages 1-22.
Crossref
Crossref
Souradeepa Ghosh, Snehlata, Shahbaj Hussain, Himani Makkar & Budhaditya Mukherjee. (2021) Role of chromatin modulation in the establishment of protozoan parasite infection for developing targeted chemotherapeutics. The Nucleus 64:3, pages 401-413.
Crossref
Crossref
Michela Giuliano, Claudia Pellerito, Adriana Celesia, Tiziana Fiore & Sonia Emanuele. (2021) Tributyltin(IV) Butyrate: A Novel Epigenetic Modifier with ER Stress- and Apoptosis-Inducing Properties in Colon Cancer Cells. Molecules 26:16, pages 5010.
Crossref
Crossref
Skye Hsin-Hsien Yeh, Ming Hsien Lin, I. I. Leo Garcia Flores, Uday Mukhopadhyay, Danial Young, Kazuma Ogawa, Jeong-Hwan Jeong, William Tong, Juri G. Gelovani & Nobuyoshi Fukumitsu. (2021) In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging. Molecular Imaging 2021, pages 1-11.
Crossref
Crossref
Mohsin Nawaz, Irfan Malik, Mudassar Hameed, Zulfiqar Hussain Kuthu & Jinlin Zhou. (2020) Modifications of histones in parasites as drug targets. Veterinary Parasitology 278, pages 109029.
Crossref
Crossref
Qijin Yin, Mengmeng Wu, Qiao Liu, Hairong Lv & Rui Jiang. (2019) DeepHistone: a deep learning approach to predicting histone modifications. BMC Genomics 20:S2.
Crossref
Crossref
Yandong Lai, Jin Li, Xiuying Li & Chunbin Zou. (2017) LPS modulates p300 and Sirt1 to promote PRMT1 stability via a SCF-Fbxl17-recognized acetyldegron. Journal of Cell Science.
Crossref
Crossref
Kathryn Hill & Tania L. Roth. 2016. Developmental Psychopathology. Developmental Psychopathology
1
26
.
MD. ALI ASGAR, GULSIRI SENAWONG, BANCHOB SRIPA & THANASET SENAWONG. (2016) Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines. International Journal of Oncology 48:1, pages 409-420.
Crossref
Crossref
Yang Cai, Xiang Yan, Guoqing Zhang, Weihong Zhao & Shunchang Jiao. (2015) The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget 6:22, pages 18997-19005.
Crossref
Crossref
S.S Mahajan & A Chavan. (2014) NEW AND EMERGING HDAC INHIBITORS FOR THE TREATMENT OF DISEASES. INDIAN DRUGS 51:06, pages 5-15.
Crossref
Crossref
Vaishali Patil & Satya Gupta. 2014. Cancer-Causing Viruses and Their Inhibitors. Cancer-Causing Viruses and Their Inhibitors
437
466
.
Asif Rizwan & Kristine Glunde. 2014. Functional Imaging in Oncology. Functional Imaging in Oncology
147
180
.
Lesley-Ann Giddings & David J Newman. (2013) Microbial natural products: molecular blueprints for antitumor drugs. Journal of Industrial Microbiology and Biotechnology 40:11, pages 1181-1210.
Crossref
Crossref
Martin Lübke, Manfred Jung & Günter Haufe. (2013) New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity. Journal of Fluorine Chemistry 152, pages 144-156.
Crossref
Crossref
Santosh Kumar & Souvik Maiti. (2013) Effect of different arginine methylations on the thermodynamics of Tat peptide binding to HIV-1 TAR RNA. Biochimie 95:7, pages 1422-1431.
Crossref
Crossref
Jatinder Goyal & Ronald Rodriguez. (2013) Evidence from clinical trials for the use of valproic acid in solid tumors: focus on prostate cancer. Clinical Investigation 3:5, pages 467-478.
Crossref
Crossref
Altaf A Dar, Shahana Majid, Claudia Rittsteuer, David de Semir, Vladimir Bezrookove, Schuyler Tong, Mehdi Nosrati, Richard Sagebiel, James R. MillerIIIIII & Mohammed Kashani-Sabet. (2013) The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression. JNCI: Journal of the National Cancer Institute 105:6, pages 433-442.
Crossref
Crossref
Mee Young Ahn, Dong O. Kang, Yong Jin Na, Sungpil Yoon, Whan Soo Choi, Keun Wook Kang, Hae Young Chung, Jee H. Jung, Do Sik Min & Hyung Sik Kim. (2012) Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Letters 325:2, pages 189-199.
Crossref
Crossref
Shirlette G. Milton, Omana P. Mathew, Frank M. Yatsu & Kasturi Ranganna. (2012) Differential Cellular and Molecular Effects of Butyrate and Trichostatin A on Vascular Smooth Muscle Cells. Pharmaceuticals 5:9, pages 925-943.
Crossref
Crossref
Giuseppe GianniniWalter Cabri, Caterina Fattorusso & Manuela Rodriquez. (2012) Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Medicinal Chemistry 4:11, pages 1439-1460.
Crossref
Crossref
Paul V. Licciardi & Tom C. Karagiannis. (2012) Regulation of Immune Responses by Histone Deacetylase Inhibitors. ISRN Hematology 2012, pages 1-10.
Crossref
Crossref
Juraj Bodo, Jan Sedlak, Jaroslaw P. Maciejewski, Alex Almasan & Eric D. Hsi. (2011) HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis 16:9, pages 914-923.
Crossref
Crossref
Wanda Baer-Dubowska, Aleksandra Majchrzak-Celińska & Michał Cichocki. (2011) Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological Reports 63:2, pages 293-304.
Crossref
Crossref
Wei Qu, Yin-dong Kang, Mei-sheng Zhou, Li-li Fu, Zhen-hao Hua & Li-ming Wang. (2010) Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urologic Oncology: Seminars and Original Investigations 28:6, pages 648-654.
Crossref
Crossref
Liwang Cui & Jun Miao. (2010) Chromatin-Mediated Epigenetic Regulation in the Malaria Parasite Plasmodium falciparum. Eukaryotic Cell 9:8, pages 1138-1149.
Crossref
Crossref
Altaf A. Dar, Shahana Majid, Mehdi Nosrati, David de Semir, Scot Federman & Mohammed Kashani-Sabet. (2010) Functional Modulation of IGF-Binding Protein-3 Expression in Melanoma. Journal of Investigative Dermatology 130:8, pages 2071-2079.
Crossref
Crossref
Pamela Munster, Douglas Marchion, Elona Bicaku, Mira Lacevic, Jongphil Kim, Barbara Centeno, Adil Daud, Anthony Neuger, Susan Minton & Daniel Sullivan. (2009) Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clinical Cancer Research 15:7, pages 2488-2496.
Crossref
Crossref
Dorte Lisbet Nielsen, Michael Andersson & Claus Kamby. (2009) HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treatment Reviews 35:2, pages 121-136.
Crossref
Crossref
S. Majid, A. A. Dar, A. E. Ahmad, H. Hirata, K. Kawakami, V. Shahryari, S. Saini, Y. Tanaka, A. V. Dahiya, G. Khatri & R. Dahiya. (2009) BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30:4, pages 662-670.
Crossref
Crossref
Franco Chimenti, Bruna Bizzarri, Elias Maccioni, Daniela Secci, Adriana Bolasco, Paola Chimenti, Rossella Fioravanti, Arianna Granese, Simone Carradori, Federica Tosi, Paola Ballario, Stefano Vernarecci & Patrizia Filetici. (2008) A Novel Histone Acetyltransferase Inhibitor Modulating Gcn5 Network: Cyclopentylidene-[4-(4′-chlorophenyl)thiazol-2-yl)hydrazone. Journal of Medicinal Chemistry 52:2, pages 530-536.
Crossref
Crossref
Stephen Gorsuch, Vassilios Bavetsias, Martin G. Rowlands, G. Wynne Aherne, Paul Workman, Michael Jarman & Edward McDonald. (2009) Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs). Bioorganic & Medicinal Chemistry 17:2, pages 467-474.
Crossref
Crossref
Shahana Majid, Altaf A. Dar, Varahram Shahryari, Hiroshi Hirata, Ardalan Ahmad, Sharanjot Saini, Yuichiro Tanaka, Angela V. Dahiya & Rajvir Dahiya. (2009) Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer, pages NA-NA.
Crossref
Crossref
Jacob Peedicayil. (2008) Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics 9:12, pages 1785-1786.
Crossref
Crossref
Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott & Amita Patnaik. (2008) Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. Clinical Cancer Research 14:20, pages 6663-6673.
Crossref
Crossref
Jacob Peedicayil. 2008. Cancer Epigenetics. Cancer Epigenetics
429
436
.
Yujun George Zheng, Jiang Wu, Ziyue Chen & Masha Goodman. (2008) Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. Medicinal Research Reviews 28:5, pages 645-687.
Crossref
Crossref
Nobuko Wakamatsu, Jennifer B. Collins, Joel S. Parker, Mathewos Tessema, Natasha P. Clayton, Thai-Vu T. Ton, Hue-Hua L. Hong, Steven Belinsky, Theodora R. Devereux, Robert C. Sills & Stephanie A. Lahousse. (2008)
Gene Expression Studies Demonstrate that the K-
ras
/Erk MAP Kinase Signal Transduction Pathway and Other Novel Pathways Contribute to the Pathogenesis of Cumene-induced Lung Tumors
. Toxicologic Pathology 36:5, pages 743-752.
Crossref
Crossref
Shahana Majid, Nobuyuki Kikuno, Jason Nelles, Emily Noonan, Yuichiro Tanaka, Ken Kawamoto, Hiroshi Hirata, Long C. Li, Hong Zhao, Steve T. Okino, Robert F. Place, Deepa Pookot & Rajvir Dahiya. (2008)
Genistein Induces the
p21WAF1/CIP1
and
p16INK4a
Tumor Suppressor Genes in Prostate Cancer Cells by Epigenetic Mechanisms Involving Active Chromatin Modification
. Cancer Research 68:8, pages 2736-2744.
Crossref
Crossref
Yuen-Li Chung, Helen Troy, Rebecca Kristeleit, Wynne Aherne, L. Elizabeth Jackson, Peter Atadja, John R. Griffiths, Ian R. Judson, Paul Workman, Martin O. Leach & Mounia Beloueche-Babari. (2008) Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts. Neoplasia 10:4, pages 303-313.
Crossref
Crossref
Nicholas D Allen. (2007) Temporal and epigenetic regulation of neurodevelopmental plasticity. Philosophical Transactions of the Royal Society B: Biological Sciences 363:1489, pages 23-38.
Crossref
Crossref
K. Yasukawa, D. Sawamura, M. Goto, H. Nakamura & H. Shimizu. (2007) Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts. British Journal of Dermatology 157:4, pages 662-669.
Crossref
Crossref
Michal Entin-Meer, Ada Rephaeli, Xiaodong Yang, Abraham Nudelman, Ayelet Nudelman & Daphne Adele Haas-Kogan. (2007) AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Letters 253:2, pages 205-214.
Crossref
Crossref
Marissa V. Powers & Paul Workman. (2007) Inhibitors of the heat shock response: Biology and pharmacology. FEBS Letters 581:19, pages 3758-3769.
Crossref
Crossref
S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D’Anneo, P. Di Fazio, R. Vento & G. Tesoriere. (2007) SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12:7, pages 1327-1338.
Crossref
Crossref
JoAnn M. Gensert, Oxana V. Baranova, David E. Weinstein & Rajiv R. Ratan. (2007) CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells. Neurobiology of Disease 26:3, pages 671-680.
Crossref
Crossref
Anthea Hardcastle, Peter Tomlin, Clair Norris, Juliet Richards, Matthew Cordwell, Katherine Boxall, Martin Rowlands, Keith Jones, Ian Collins, Edward McDonald, Paul Workman & Wynne Aherne. (2007) A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Molecular Cancer Therapeutics 6:3, pages 1112-1122.
Crossref
Crossref
J.L. Holmes, S.Y. Sharp & P. Workman. 2007. Heat Shock Proteins in Cancer. Heat Shock Proteins in Cancer
295
330
.
Julius Leyton, John P. Alao, Marco Da Costa, Alexandra V. Stavropoulou, John R. Latigo, Meg Perumal, Radhakrishna Pillai, Qimin He, Peter Atadja, Eric W.-F. Lam, Paul Workman, David M. Vigushin & Eric O. Aboagye. (2006)
In vivo
Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography
. Cancer Research 66:15, pages 7621-7629.
Crossref
Crossref
Vincent P. Gullo, James McAlpine, Kin S. Lam, Dwight Baker & Frank Petersen. (2006) Drug discovery from natural products. Journal of Industrial Microbiology & Biotechnology 33:7, pages 523-531.
Crossref
Crossref
Walter M. Stadler, Kim Margolin, Sandy Ferber, William McCulloch & John A. Thompson. (2006) A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer. Clinical Genitourinary Cancer 5:1, pages 57-60.
Crossref
Crossref
Mehdi Ouaissi & Ali Ouaissi. (2006) Histone Deacetylase Enzymes as Potential Drug Targets in Cancer and Parasitic Diseases. Journal of Biomedicine and Biotechnology 2006, pages 1-10.
Crossref
Crossref
Douglas C. Marchion, Elona Bicaku, Adil I. Daud, Daniel M. Sullivan & Pamela N. Munster. (2005)
In vivo
synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
. Molecular Cancer Therapeutics 4:12, pages 1993-2000.
Crossref
Crossref
Tijana Mitiæ & Jennifer S. McKay. (2016) Immunohistochemical Analysis of Acetylation, Proliferation, Mitosis, and Apoptosis in Tumor Xenografts Following Administration of a Histone Deacetylase Inhibitor—A Pilot Study. Toxicologic Pathology 33:7, pages 792-799.
Crossref
Crossref
Lindsay Stimson, Martin G. Rowlands, Yvette M. Newbatt, Nicola F. Smith, Florence I. Raynaud, Paul Rogers, Vassilios Bavetsias, Stephen Gorsuch, Michael Jarman, Andrew Bannister, Tony Kouzarides, Edward McDonald, Paul Workman & G. Wynne Aherne. (2005) Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Molecular Cancer Therapeutics 4:10, pages 1521-1532.
Crossref
Crossref
Milin R. Acharya, Alex Sparreboom, Jürgen Venitz & William D. Figg. (2005) Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. Molecular Pharmacology 68:4, pages 917-932.
Crossref
Crossref
Patrick Angibaud, Janine Arts, Kristof Van Emelen, Virginie Poncelet, Isabelle Pilatte, Bruno Roux, Sven Van Brandt, Marc Verdonck, Hans De Winter, Peter Ten Holte, Ann Marien, Wim Floren, Boudewijn Janssens, Jacky Van Dun, An Aerts, Jacky Van Gompel, Sandrine Gaurrand, Laurence Queguiner, Jean-Michel Argoullon, Luc Van Hijfte, Eddy Freyne & Michel Janicot. (2005) Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. European Journal of Medicinal Chemistry 40:6, pages 597-606.
Crossref
Crossref
Paul Workman. (2005) Genomics and the second golden era of cancer drug development. Molecular BioSystems 1:1, pages 17.
Crossref
Crossref
Ann L. Jackman, Stanley Kaye & Paul Workman. (2004) The combination of cytotoxic and molecularly targeted therapies – can it be done?. Drug Discovery Today: Therapeutic Strategies 1:4, pages 445-454.
Crossref
Crossref
Paul A. Clarke, Robert te Poele & Paul Workman. (2004) Gene expression microarray technologies in the development of new therapeutic agents. European Journal of Cancer 40:17, pages 2560-2591.
Crossref
Crossref